Amicus Therapeutics, Inc. to Host Conference Call Today at 8:00 a.m. ET to Discuss Regulatory Strategy for Migalastat HCl Monotherapy for Fabry Disease

Published: Jun 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CRANBURY, N.J., June 17, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced that John F. Crowley, Chairman and Chief Executive Officer, will host a conference call at 8:00 a.m. ET this morning. Mr. Crowley will highlight the regulatory strategy for migalastat HCl monotherapy for Fabry disease following a recent Type C meeting with the U.S. Food and Drug Administration (FDA).

Help employers find you! Check out all the jobs and post your resume.

Back to news